RXRX
Income statement / Annual
Last year (2023), Recursion Pharmaceuticals, Inc.'s total revenue was $44.58 M,
an increase of 12.33% from the previous year.
In 2023, Recursion Pharmaceuticals, Inc.'s net income was -$328.07 M.
See Recursion Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$44.58 M
|
$39.68 M
|
$10.00 M
|
$3.41 M
|
$1.71 M
|
| Cost of Revenue |
$42.59 M |
$48.28 M |
$9.10 M |
$63.32 M |
$45.81 M |
| Gross Profit |
$1.99 M |
-$8.59 M |
$896,000.00 |
-$59.91 M |
-$44.10 M |
| Gross Profit Ratio |
0.04 |
-0.22 |
0.09 |
-17.55 |
-25.77 |
| Research and Development
Expenses |
$241.23 M
|
$155.70 M
|
$135.27 M
|
$63.32 M
|
$45.81 M
|
| General & Administrative
Expenses |
$110.82 M
|
$81.60 M
|
$57.68 M
|
$25.26 M
|
$18.95 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$110.82 M
|
$81.60 M
|
$57.68 M
|
$25.26 M
|
$18.95 M
|
| Other Expenses |
-$699,000.00 |
-$162,000.00 |
-$178,000.00 |
-$549,000.00 |
-$608,000.00 |
| Operating Expenses |
$351.35 M |
$237.13 M |
$192.78 M |
$88.03 M |
$64.15 M |
| Cost And Expenses |
$394.64 M |
$285.41 M |
$192.78 M |
$88.03 M |
$64.15 M |
| Interest Income |
$19.12 M |
$6.25 M |
$73,000.00 |
$336,000.00 |
$1.74 M |
| Interest Expense |
$97,000.00 |
$55,000.00 |
$2.95 M |
$1.36 M |
$635,000.00 |
| Depreciation &
Amortization |
$24.40 M
|
$19.49 M
|
$9.10 M
|
$4.44 M
|
$3.54 M
|
| EBITDA |
-$299.57 M
|
-$227.67 M
|
-$174.42 M
|
-$81.70 M
|
-$58.34 M
|
| EBITDA Ratio |
-6.72 |
-6.19 |
-18.28 |
-23.53 |
-34.02 |
| Operating Income Ratio
|
-7.85
|
-6.19
|
-18.28
|
-24.79
|
-36.49
|
| Total Other
Income/Expenses Net |
$17.93 M
|
$6.25 M
|
-$3.70 M
|
-$2.39 M
|
$562,000.00
|
| Income Before Tax |
-$332.13 M |
-$239.48 M |
-$186.48 M |
-$87.01 M |
-$61.88 M |
| Income Before Tax Ratio
|
-7.45
|
-6.04
|
-18.65
|
-25.49
|
-36.17
|
| Income Tax Expense |
-$4.06 M |
-$55,000.00 |
-$8.41 M |
$876,000.00 |
$646,000.00 |
| Net Income |
-$328.07 M |
-$239.42 M |
-$178.07 M |
-$87.88 M |
-$62.53 M |
| Net Income Ratio |
-7.36 |
-6.03 |
-17.81 |
-25.75 |
-36.54 |
| EPS |
-1.58 |
-1.36 |
-1.05 |
-0.5248 |
-0.3732 |
| EPS Diluted |
-1.58 |
-1.36 |
-1.05 |
-0.5248 |
-0.3732 |
| Weighted Average Shares
Out |
$207.85 M
|
$175.54 M
|
$170.27 M
|
$165.79 M
|
$165.79 M
|
| Weighted Average Shares
Out Diluted |
$207.85 M
|
$175.54 M
|
$170.27 M
|
$165.79 M
|
$165.79 M
|
| Link |
|
|
|
|
|
